In a recent survey, Industry Standard Research asked respondents their level of agreement regarding several trends in the Phase I space to assess the direction in which their organization’s interest is heading. About 60% of respondents indicate their organization’s interest in diagnostic development is increasing. The growing interest in diagnostic development ties in with recent growth in rare disease and precision medicine. Conversely, over half of respondents disagree that their company’s interest in challenge trials (those in which participants are intentionally challenged with an infectious disease organism) is increasing. About one-fifth of respondents disagreed with this strongly.

Originally published in Life Science Leader.

View File